EA201891303A1 - ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ - Google Patents

ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

Info

Publication number
EA201891303A1
EA201891303A1 EA201891303A EA201891303A EA201891303A1 EA 201891303 A1 EA201891303 A1 EA 201891303A1 EA 201891303 A EA201891303 A EA 201891303A EA 201891303 A EA201891303 A EA 201891303A EA 201891303 A1 EA201891303 A1 EA 201891303A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
pharmaceutically acceptable
acceptable salts
derivatives
pulmonary
Prior art date
Application number
EA201891303A
Other languages
English (en)
Other versions
EA036445B1 (ru
Inventor
Рафелл Берджер
И-Хэн Чэнь
Гоцин Ли
Джои Гарфанкл
Хун Ли
Шоуву Мяо
Субхарекха Рагхаван
Камерон Дж. Смит
Джон Стелмач
Алан Уайтхед
Жуй Чжан
Юн Чжан
Цзяньминь Фу
Ган Цзи
Фалун Цзян
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of EA201891303A1 publication Critical patent/EA201891303A1/ru
Publication of EA036445B1 publication Critical patent/EA036445B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Изобретение относится к соединениям формулы (I) или их фармацевтически приемлемым солям, где X, Y, Z, R, R, R, Rи нижние индексы m, p и q представляют собой то, что раскрыто в настоящем описании. Соединения или их фармацевтически приемлемые соли могут модулировать в организме продуцирование циклического гуанозинмонофосфата ("cGMP") и в целом подходят для терапии и профилактики заболеваний, которые связаны с нарушенным балансом cGMP, таких как сердечно-сосудистое заболевание, нарушение эндотелиальной функции, нарушение диастолической функции, атеросклероз, гипертензия, сердечная недостаточность, легочная гипертензия (группы I, II, III, IV по WHO), стенокардия, тромбоз, рестеноз, инфаркт миокарда, инсульт, сердечная декомпенсация, фиброз, легочная гипертония, нарушение эректильной функции, астма, острый респираторный дистресс синдром (ARDS), хроническая почечная недостаточность, кистозный фиброз, серповидноклеточная анемия, склеродермия, синдром Рейно, диабет, диабетическая ретинопатия, цирроз печени, хроническое обструктивное заболевание легких (COPD), острое повреждение легких, фиброз легких или интерстициальное заболевание легких. Изобретение также относится к фармацевтическим композициям, которые содержат соединения формулы (I) или их фармацевтически приемлемые соли. Изобретение также относится к соединениям или их фармацевтически приемлемым солям для использования в терапии и профилактике вышеуказанных заболеваний и для получения фармацевтических средств с этой целью.
EA201891303A 2015-12-22 2016-12-20 ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ EA036445B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/098251 WO2017107052A1 (en) 2015-12-22 2015-12-22 Soluble guanylate cyclase stimulators
PCT/US2016/067654 WO2017112617A1 (en) 2015-12-22 2016-12-20 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases

Publications (2)

Publication Number Publication Date
EA201891303A1 true EA201891303A1 (ru) 2018-11-30
EA036445B1 EA036445B1 (ru) 2020-11-11

Family

ID=57758775

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891303A EA036445B1 (ru) 2015-12-22 2016-12-20 ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

Country Status (39)

Country Link
US (2) US10030027B2 (ru)
EP (1) EP3394067B1 (ru)
JP (1) JP6454448B2 (ru)
KR (1) KR102191312B1 (ru)
CN (1) CN108738320B (ru)
AR (1) AR107154A1 (ru)
AU (1) AU2016377364B2 (ru)
BR (1) BR112018012579B8 (ru)
CA (1) CA3009193C (ru)
CL (1) CL2018001671A1 (ru)
CO (1) CO2018006300A2 (ru)
CR (1) CR20180330A (ru)
CY (1) CY1123173T1 (ru)
DK (1) DK3394067T3 (ru)
DO (1) DOP2018000153A (ru)
EA (1) EA036445B1 (ru)
EC (1) ECSP18054606A (ru)
ES (1) ES2794654T3 (ru)
HK (1) HK1255028A1 (ru)
HR (1) HRP20200857T1 (ru)
HU (1) HUE049941T2 (ru)
IL (1) IL260020B (ru)
LT (1) LT3394067T (ru)
ME (1) ME03748B (ru)
MX (2) MX2018007728A (ru)
MY (1) MY194021A (ru)
NI (1) NI201800069A (ru)
PE (1) PE20181802A1 (ru)
PH (1) PH12018501342A1 (ru)
PL (1) PL3394067T3 (ru)
PT (1) PT3394067T (ru)
RS (1) RS60344B1 (ru)
SG (1) SG11201805272XA (ru)
SI (1) SI3394067T1 (ru)
SV (1) SV2018005715A (ru)
TN (1) TN2018000219A1 (ru)
TW (1) TWI724079B (ru)
UA (1) UA122264C2 (ru)
WO (2) WO2017107052A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
EP3458063A4 (en) 2016-05-18 2020-02-26 Merck Sharp & Dohme Corp. METHODS OF USING TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR FIBROTIC DISORDERS
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3609883B1 (en) * 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
EP3787610A1 (en) 2018-04-30 2021-03-10 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
AU6691498A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE19744027A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
WO2009001836A1 (en) 2007-06-28 2008-12-31 Semiconductor Energy Laboratory Co., Ltd. Manufacturing method of semiconductor device
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
CA2693214A1 (en) 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9365574B2 (en) * 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX2013000198A (es) 2010-07-09 2013-01-28 Bayer Ip Gmbh Pirimidinadas y triazinas condensadas y su uso.
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
KR20140050029A (ko) 2011-07-06 2014-04-28 바이엘 인텔렉쳐 프로퍼티 게엠베하 헤테로아릴-치환된 피라졸로피리딘 및 가용성 구아닐레이트 시클라제 자극제로서의 그의 용도
JP6054967B2 (ja) 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アネレート化ピリミジンおよびその使用
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
PE20160201A1 (es) 2013-07-10 2016-05-06 Bayer Pharma AG Bencil-1h-pirazol[3,4-b]piridinas y su uso
WO2015088885A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
CN108463224A (zh) 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
BR112018015718A2 (pt) 2016-02-01 2019-01-08 Ironwood Pharmaceuticals Inc utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)

Also Published As

Publication number Publication date
TW201734017A (zh) 2017-10-01
PL3394067T3 (pl) 2020-08-24
AU2016377364B2 (en) 2019-02-14
ECSP18054606A (es) 2018-12-31
MY194021A (en) 2022-11-08
ES2794654T3 (es) 2020-11-18
SV2018005715A (es) 2018-10-19
SG11201805272XA (en) 2018-07-30
TN2018000219A1 (en) 2019-10-04
BR112018012579A2 (pt) 2018-12-04
JP6454448B2 (ja) 2019-01-16
US10428076B2 (en) 2019-10-01
BR112018012579B8 (pt) 2023-11-21
US20180305366A1 (en) 2018-10-25
AR107154A1 (es) 2018-03-28
DK3394067T3 (da) 2020-06-15
EP3394067B1 (en) 2020-04-01
HRP20200857T1 (hr) 2020-11-13
EP3394067A1 (en) 2018-10-31
EA036445B1 (ru) 2020-11-11
CO2018006300A2 (es) 2018-07-10
HUE049941T2 (hu) 2020-11-30
SI3394067T1 (sl) 2020-07-31
CY1123173T1 (el) 2021-10-29
WO2017112617A1 (en) 2017-06-29
KR102191312B1 (ko) 2020-12-15
PT3394067T (pt) 2020-06-02
NI201800069A (es) 2018-10-05
AU2016377364A1 (en) 2018-06-14
US20170174693A1 (en) 2017-06-22
BR112018012579B1 (pt) 2023-10-24
LT3394067T (lt) 2020-06-10
KR20180095904A (ko) 2018-08-28
PE20181802A1 (es) 2018-11-19
IL260020B (en) 2021-05-31
MX2018007728A (es) 2018-08-15
TWI724079B (zh) 2021-04-11
UA122264C2 (uk) 2020-10-12
CN108738320A (zh) 2018-11-02
DOP2018000153A (es) 2018-11-30
CA3009193A1 (en) 2017-06-29
US10030027B2 (en) 2018-07-24
CN108738320B (zh) 2021-11-19
PH12018501342A1 (en) 2019-02-18
CA3009193C (en) 2020-09-15
MX2020011080A (es) 2020-11-06
CR20180330A (es) 2018-08-21
RS60344B1 (sr) 2020-07-31
ME03748B (me) 2021-04-20
HK1255028A1 (zh) 2019-08-02
WO2017107052A1 (en) 2017-06-29
JP2018538333A (ja) 2018-12-27
IL260020A (en) 2018-07-31
CL2018001671A1 (es) 2018-08-03

Similar Documents

Publication Publication Date Title
EA201891303A1 (ru) ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
AU2022201816A8 (en) Pyrrolopyrimidines as CFTR potentiators
PH12018500088A1 (en) Substituted tricyclics and method of use
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
EA201391769A1 (ru) Имидазопиридиновые соединения
MX2017006649A (es) Derivados de triazolo-pirazinilo utiles como activadores de guanilato ciclasa soluble.
MX2019007135A (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
NZ610012A (en) Compositions and methods of treating pulmonary hypertension
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
CR20120280A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
JP2014505713A (ja) Ｃｎｓ障害の処置のための６−シクロアルキル−ピラゾロピリミジノン
JP2020007357A (ja) 有機化合物
TW200628451A (en) Novel pyrimidine derivatives and their use
EA201792134A1 (ru) Гетероциклилметилтиеноурацилы в качестве антагонистов аденозин а2в рецептора
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
Ugliarolo et al. Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols
UA110933C2 (uk) Композиція для лікування есенціальної тромбоцитемії
NZ610866A (en) Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient
Reviriego Cenicriviroc mesylate

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM